Teleflex Price Target | Analysis, Price & Growth Outlook

Teleflex

NYSE:TFX

$ 116,22

+ $5,73 (5,19%)

116,22 $

+$5,73 (5,19%)

End-of-day quote: 03/27/2026

Teleflex Stock Value

Analysts currently rate Teleflex as Hold.

Hold

Teleflex Company Info

EPS Growth 5Y

4,67%

Market Cap

$5,14 B

Long-Term Debt

$1,56 B

Short Interest

2,15%

Quarterly earnings

05/01/2026 (E)

Dividend

$1,43

Dividend Yield

1,23%

Founded

1943

Industry

Health Care

Country

United States

ISIN Number

US8793691069

Website

http://www.teleflex.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$130,00

11.86%

Last Update: 03/29/2026

Analysts: 9

Highest Price Target $147,00

Average Price Target $130,00

Lowest Price Target $115,00

In the last five quarters, Teleflex’s Price Target has fallen from $470,07 to $236,68 - a -49,65% decrease. Six analysts predict that Teleflex’s share price will increase in the coming year, reaching $130,00. This would represent an increase of 11,86%.

Top growth stocks in the health care sector (5Y.)

What does Teleflex do?

Teleflex Incorporated (‘Teleflex’) is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The company markets and sells its products to hospitals and healthcare providers worldwide through a combination...

Teleflex Incorporated (‘Teleflex’) is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety.

The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

The company markets and sells its products to hospitals and healthcare providers worldwide through a combination of its direct sales force and distributors. Because the company’s products are used in numerous markets and for a variety of procedures, it is not dependent upon any one end-market or procedure. The company’s major manufacturing operations are located in the Czech Republic, Malaysia, Mexico, and the United States (the ‘U.S.’).

The company’s portfolio of existing products and products under development consists primarily of Class I and Class II medical devices, most of which require 510(k) clearance by the U.S. Food and Drug Administration ("FDA") for sale in the U.S., and some of which are exempt from the requirement to obtain 510(k) clearance.

On February 27, 2025, the company announced its intention to create a new, independently traded public company comprising Urology (consisting of its Interventional Urology and Urology product categories), Acute Care (consisting of the company’s Respiratory product category, the majority of its Anesthesia product category, and certain products within its Interventional Access and Surgical product categories), and its OEM businesses. The company’s Vascular Access product category, most of its products within its Interventional Access and Surgical product categories, and the Vascular Intervention business expected to be acquired from BIOTRONIK SE & Co. KG will remain with Teleflex.

Segments

The company has three reportable segments: Americas, EMEA (Europe, the Middle East, and Africa), and Asia (Asia Pacific).

Each of the company’s three geographic segments provides a comprehensive portfolio of medical technology products used by hospitals and healthcare providers.

Products

The company’s product categories within its geographic segments include vascular access, anesthesia, interventional, surgical, interventional urology, respiratory, and urology. Each of these categories and the key products sold therein are described in more detail below.

Vascular Access: The company’s Vascular Access product portfolio encompasses devices designed to support a variety of critical care therapies and other medical applications, with an emphasis on reducing vascular-related complications. These products primarily include the company’s Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems.

The company’s catheters are designed to support a wide array of clinical procedures, including the administration of intravenous therapies, the measurement of blood pressure, and the collection of blood samples, all through a single puncture site. Many of these catheters are equipped with antimicrobial and anti-thrombogenic protection technologies, which have been demonstrated to reduce the risk of catheter-related bloodstream infections, microbial colonization, and thrombus formation on catheter surfaces.

The company’s intraosseous access systems are designed for the delivery of medications and fluids in situations where intravenous access is challenging or not feasible. These systems are particularly effective in emergency, urgent, or medically critical scenarios and are suitable for use in both hospital and pre-hospital settings. Key products in this line include the EZ-IO Intraosseous Vascular Access System and the Arrow FAST1 Sternal Intraosseous Infusion System.

Interventional: The company’s Interventional product category offers devices that facilitate a variety of applications to diagnose and deliver treatment of coronary and peripheral vascular disease. These products primarily consist of a diverse portfolio of coronary catheters, structural heart support devices, peripheral intervention products, and mechanical circulatory support platforms used by interventional cardiologists, interventional radiologists, and vascular surgeons. Clinical benefits of the company’s products include increased vein and artery access, post-procedure closure, and increased support during complex medical procedures. The company’s primary product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike, and TrapLiner catheters, the MANTA Vascular Closure device, and Arrow OnControl powered bone biopsy system.

Anesthesia: The company’s Anesthesia product category consists of airway, pain management, and hemostatic product lines that support hospital, emergency medicine, and military channels.

The company’s airway management products and related devices are designed to enable the use of standard and advanced anesthesia techniques in both pre-hospital emergency and hospital settings. The company’s key products include laryngoscopes, supraglottic airways, endotracheal tubes, and atomization devices, which are branded under its LMA, Rusch, and MAD trade names.

The company’s pain management product line includes epidurals, catheters, and disposable pain pumps for regional anesthesia, designed to improve patients’ post-operative pain experience, which are branded under its Arrow trade name.

The company’s hemostatic products accelerate the body's natural clotting cascade and are used in trauma situations where bleeding is difficult to control. The portfolio consists of external hemostats used by first responders, interventional products used in the catheter lab, and trauma products used by trauma surgeons, which are branded under its QuikClot trade name.

Surgical: The company’s Surgical product category consists of single-use and reusable devices designed for use in a variety of surgical procedures. These products primarily consist of metal and polymer ligating clips, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, a powered bariatric stapler, and other surgical instruments used in Ear, Nose, and Throat, and Cardiovascular and Thoracic procedures. The company’s significant surgical brands include Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS.

Interventional Urology: The company’s Interventional Urology product category includes the UroLift System, a minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. The UroLift System involves the placement of permanent implants, typically through a transurethral outpatient procedure, that holds the prostate lobes apart to relieve compression on the urethra without cutting, heating, or removing prostate tissue. In 2023, the company expanded its product portfolio with the acquisition of Palette Life Sciences AB (‘Palette’), which adds a portfolio of hyaluronic acid gel-based products primarily utilized in the treatment of urological diseases, including Barrigel, a rectal spacing product used in connection with radiation therapy treatment of prostate cancer. The company’s Interventional Urology product portfolio is most heavily weighted in its Americas segment.

Respiratory: The company’s respiratory products are used in a variety of care settings and primarily consist of humidification and oxygen therapy products. This product category previously included aerosol therapy, spirometry, and ventilation management products, as well as certain other oxygen therapy products, all of which were included in the Respiratory business divestiture.

Urology: The company’s urology product portfolio provides bladder management for patients in the hospital and individuals in the home care markets. The product portfolio consists principally of a wide range of catheters (including Foley and intermittent), urine collectors, catheterization accessories, and products for operative endourology, which are marketed under the Teleflex and Rusch brand names. The company’s urology product portfolio is most heavily weighted in the company’s EMEA segment.

OEM: The company’s OEM product category designs, manufactures, and supplies devices and instruments for other medical device manufacturers. The company’s OEM portfolio, which includes the TFX Medical OEM, TFX OEM, Deknatel, and HPC Medical brands, provides custom extrusions, micro-diameter film-cast tubing, diagnostic and interventional catheters, balloons and balloon catheters, film-insulated fine wire, coated mandrel wire, conductors, sheath/dilator introducers, specialized sutures and performance fibers, bioabsorbable sutures, yarns, and resins. The company’s OEM product portfolio is presented within its Americas segment.

Markets

The company generally serves three end-markets: hospitals and healthcare providers, medical device manufacturers, and home care. These markets are affected by a number of factors, including demographics, utilization, and reimbursement patterns.

Government Regulation

All of the company’s medical devices manufactured or distributed in the U.S. are subject to requirements set forth by the Federal Food, Drug, and Cosmetic Act (‘FDC Act’) and regulations promulgated by the FDA under the FDC Act, which are enforced by the FDA.

Unless an exemption, pre-amendment grandfather status (that is, medical devices legally marketed in the U.S. before May 28, 1976), or FDA enforcement discretion applies, each medical device that the company markets in the U.S. must first receive either clearance as a Class I or, typically, a Class II device (after submitting a premarket notification (‘510(k)’) or approval as a Class III device (after filing a premarket approval application (‘PMA’)) from the FDA pursuant to the FDC Act. To obtain 510(k) clearance, a manufacturer must demonstrate to the FDA that the proposed device is substantially equivalent to a legally marketed device (a 510(k)-cleared device, a pre-amendment device for which the FDA has not called for PMAs, or a device with a de novo authorization), referred to as the ‘predicate device.’ The company’s portfolio of existing products and pipeline of potential new products consist primarily of Class I (510(k) exempt) and Class II devices that require 510(k) clearance, although a few are 510(k)-exempt.

Certain of the company’s medical devices are sold in kits that include a drug component, such as lidocaine. These types of kits are generally regulated as combination products within the Center for Devices and Radiological Health (‘CDRH’) under the device regulations because the device provides the primary mode of action of the kit.

The company’s manufacturing facilities, as well as those of certain of its suppliers, are subject to periodic and for-cause inspections by FDA personnel to verify compliance with the QSR (21 CFR Part 820), as well as other regulatory requirements. Similar inspections and audits are performed by Notified Bodies to verify compliance with applicable ISO standards (e.g., ISO 13485:2016), by auditing organizations under the Medical Device Single Audit Program (‘MDSAP’) applicable to regulatory requirements of Australia, Brazil, Canada, Japan, and the U.S., and/or by regulatory authorities to verify compliance with medical device regulations and requirements from the countries in which the company distributes products.

The company is subject to various federal and state reporting and disclosure requirements related to the healthcare industry. Rules issued by the Centers for Medicare & Medicaid Services (‘CMS’) require the company to collect and report information on payments or transfers of value to physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as investment interests held by physicians and their immediate family members.

The company is also subject to the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws applicable in jurisdictions outside the U.S. that generally prohibit companies and their intermediaries from improperly offering or paying anything of value to non-U.S. government officials for the purpose of obtaining or retaining business. In the sale, delivery, and servicing of the company’s medical devices and software outside of the U.S., it must also comply with various export control and trade embargo laws and regulations, including those administered by the Department of Treasury’s Office of Foreign Assets Control (‘OFAC’) and the Department of Commerce’s Bureau of Industry and Security (‘BIS’), which may require licenses or other authorizations for transactions relating to certain countries and/or with certain individuals identified by the U.S. government.

Sales and Marketing

The company’s product sales are made directly to hospitals, healthcare providers, distributors, and to original equipment manufacturers of medical devices through its own sales forces, independent representatives, and independent distributor networks.

Patents and Trademarks

The company does not consider any single patent or trademark, except for the Teleflex name and the Arrow brand, to be essential to the operation of its business.

Seasonality

Portions of the company’s revenues are subject to seasonal fluctuations. The incidence of flu and other disease patterns and, to a lesser extent, the frequency of elective medical procedures affect revenues related to single-use products. Historically, the company has experienced higher sales in the fourth quarter (year ended December 2024) as a result of these factors.

History

Teleflex Incorporated was founded in 1943. The company, a Delaware corporation, was incorporated in 1943.

Teleflex Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Medical Devices:** 100% (2025) **TOP 3 Markets:** 1. **USA:** approximately 55% 2. **Europe:** approximately 25% 3. **Asia-Pacific:** approximately 15% Teleflex Incorporated is a company specializing in the manufacturing and distribution of medical devices. The majority of revenues come from the...

At which locations are the company’s products manufactured?

**Production Sites:** USA, Mexico, Germany, Czech Republic, Malaysia, China Teleflex Incorporated is a globally operating company that develops and produces medical technologies. The production facilities are strategically located in different countries to ensure proximity to key markets as well as...

What strategy does Teleflex pursue for future growth?

**Revenue Growth:** 8.5% (estimated 2024) **R&D Investments:** 7.2% of revenue (2024) Teleflex Incorporated pursues a growth strategy that heavily relies on innovation and geographical expansion. The company consistently invests in research and development to expand its product range and de...

Which raw materials are imported and from which countries?

**Main raw materials:** Plastics, metals, silicones **Main supplying countries:** China, Germany, Mexico Teleflex Incorporated, a company in the field of medical technology, imports various raw materials necessary for the production of their products. These include primarily plastics, metals, and...

How strong is the company’s competitive advantage?

**Market Share:** Estimated at 12% in the global market for medical devices (2025). **Research & Development:** Investments of approximately 6% of revenue in R&D (2024). **Patent Portfolio:** Over 1,400 active patents (2025). Teleflex Incorporated has a significant competitive advantage i...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 90% (estimated for 2025) **Insider Buys/Sells:** No significant transactions in the last year (estimated for 2025) The institutional investor share at Teleflex Incorporated is traditionally high, indicating the trust of large investment funds and institutional inv...

What percentage market share does Teleflex have?

**Market share of Teleflex Incorporated:** Estimated around 8% (2025) **Main competitors and their market shares:** 1. **Medtronic plc:** around 15% 2. **Boston Scientific Corporation:** around 12% 3. **Becton, Dickinson and Company (BD):** around 10% 4. **Stryker Corporation:** around 9% 5. **Tele...

Is Teleflex stock currently a good investment?

**Revenue Growth:** 7.8% (2024) **Profit Growth:** 6.5% (2024) **Research & Development (R&D) Expenses:** 5.2% of Revenue (2024) Teleflex Incorporated recorded a revenue growth of 7.8% in 2024, indicating solid demand for its medical products and solutions. The profit growth of 6.5% shows t...

Does Teleflex pay a dividend – and how reliable is the payout?

**Dividend Yield:** 0.9% (2023) **Dividend History:** Continuous payout for over 10 years Teleflex Incorporated pays a dividend, with the dividend yield standing at approximately 0.9% in 2023. The company has a long history of dividend payments and is known for its reliability in distribution....

New support ticket

Explore

Teleflex Stock Value

Teleflex Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Teleflex do?

Teleflex Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Teleflex Stock Value

Teleflex Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Teleflex do?

Teleflex Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.